期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 18, 期 4, 页码 409-423出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2018.1430762
关键词
Cardiac regeneration; cardiac stem cells; somatic reprogramming; genome editing; non-coding RNAs
资金
- Italian Ministry of Research (M.I.U.R.) [2015ZTT5KB_004, RBFR12I3KA, PON03PE_00009_2-iCARE]
- Italian Ministry of Health [GR-2010-2318945]
Introduction: The characterization of multipotent endogenous cardiac stem cells (eCSCs) and the breakthroughs of somatic cell reprogramming to boost cardiomyocyte replacement have fostered the prospect of achieving functional heart repair/regeneration.Areas covered: Allogeneic CSC therapy through its paracrine stimulation of the endogenous resident reparative/regenerative process produces functional meaningful myocardial regeneration in pre-clinical porcine myocardial infarction models and is currently tested in the first-in-man human trial. The in vivo test of somatic reprogramming and cardioregenerative non-coding RNAs revived the interest in gene therapy for myocardial regeneration. The latter, together with the advent of genome editing, has prompted most recent efforts to produce genetically-modified allogeneic CSCs that secrete cardioregenerative factors to optimize effective myocardial repair.Expert opinion: The current war against heart failure epidemics in western countries seeks to find effective treatments to set back the failing hearts prolonging human lifespan. Off-the-shelf allogeneic-genetically-modified CSCs producing regenerative agents are a novel and evolving therapy set to be affordable, safe, effective and available at all times for myocardial regeneration to either prevent or treat heart failure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据